eli lilly retatrutide press release 2024 2025 touts strong results of new experimental weight loss drug Retatrutide may become one of
Description
The glucagon-like peptide 1 (GLP-1) market has witnessed robust growth, expanding from $22.06 billion in 2025 to an expected $23.88 billion in 2026, at a compound annual growth rate (CAGR) of 8.2%
GLP-1 agonists directly bind to and activate GLP-1 receptors on pancreatic cells, while berberine works primarily through AMPK activation and does not directly interact with GLP-1 receptors
Pastries, donuts, cookies, and sugary drinks (including alcohol, soda, or any juices): These should also be limited or avoided due to high calories and low nutritional value
Early rodent studies showed an increased rate of C-cell tumors after prolonged GLP-1 exposure
E.BarnesD
Limited long-term safety data, potential risks such as thyroid tumors and pancreatitis, high costs, and accessibility challenges, particularly in resource-constrained settings, can limit usage
